Q3 Report Nov. 10 after close | RGLS Message Board Posts


Regulus Therapeutics Inc.

  RGLS website

RGLS   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  766 of 846  at  11/11/2021 5:31:28 AM  by

Dendrimer


 In response to msg 765 by  Steve_382
view thread

Re: Q3 Report Nov. 10 after close

 Thanks for the updates Steve. Regarding cash, there's also the $25M from Sanofi for completing the Alport phase 2 trial which I believe is due at the end of phase 2. The trial record was last updated in Sep 21 and is about a year placebo controlled followed by a year open label and is now due to complete in Dec 23. Target enrolment is 45 patients and they have 23 centres recruiting around the world which should mitigate any frther covid delays. To meet the Dec 23 completion date they must be about to complete enrolment.
 
In terms of the milestone payment, I wonder what counts as the end of phase 2? Is it the end of blinded part of the study or the end of the open label part? Hopefully its the former and the cash will arrive before they have to access alternative sources of finance. 


     e-mail to a friend      printer-friendly     add to library      
|  
Recs: 2  
   Views: 0 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
769 Re: Q3 Report Nov. 10 after close arthurs1 0 11/17/2021 1:38:51 PM




Financial Market Data provided by
.
Loading...